Estrogen, statins, and essential fatty acids and their metabolites can prevent osteoporosis. However, it is not certain how these three structurally different agents can have the same beneficial action. It is suggested that all three, in addition to their other modes of action in the prevention of osteoporosis, have the ability to augment constitutional (or endothelial) nitric oxide generation, which is known to be beneficial in osteoporosis. If so, it will be interesting to study whether nitric oxide donors and/or nitric oxide precursors can be given together with estrogen, statins, or essential fatty acids to potentiate their benefit in osteoporosis.
KongY-Y, YoshidaHY, SarosiI, TanH-L, TimmsE, CapparelliC, MoronyS, Oliveira-dos-SantosAJ, VanG, ItieA, KhooW, WakehamA, DunstanCR, LaceyDL, MakTW, BoyleWJ, PenningerJM. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature397: 315–323, 1999.
3.
MiossecP, BriolayJ, DechanetJ, WijdenesJ, Martinez-ValdezH, BanchereauJ. Inhibition of the production of proinflammatory cytokines and immunoglobulins by interleukin-4 in an ex vivo model of rheumatoid synovitis. Arthritis Rheum35: 874–883, 1992.
4.
PacificR, BrownC, PuscheckE, FrederichE, SlatopolskyE, MaggioD, McCrackenR, AvioliLV. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci U S A88: 5134–5138, 1991.
5.
FinkelmanRD, BellNH, StrongDD, DemersLM, BaylinkDJ. Ovariectomy selectively reduces the concentration of transforming growth factor-ß in rat bone: implications for estrogen deficiency-associated bone loss. Proc Natl Acad Sci U S A89: 12190–12193, 1992.
6.
AscroftGS, DodsworthJ, van BoxtelE, TarnuzzerRW, HoranMA, SchultzGS, FergusonMW. Estrogen accelerates cutaneous wound healing associated with increase in TGF-ß1 levels. Nat Med3: 1209–1215, 1997.
7.
DasUN. Transforming growth factor-ß: Is it an endogenous cardioprotector?Med Sci Res21: 373–375, 1993.
SunyerT, LewisJ, Collin-OsdobyP, OsdobyP. Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. J Clin Invest103: 1409–1418, 1999.
10.
RotheL, Collin-OsdobyP, ChenY, SunyerT, ChaudharyL, TsayA, GoldringS, AvioliL, OsdobyP. Human osteoclasts and osteoclast-like cells synthesize and release high basal and inflammatory stimulated levels of the potent chmokine IL-8. Endocrinology139: 4353–4363, 1998.
11.
FullerK, OwensJM, ChambersTJ. Macrophage inflammatory protein- lα and IL-8 stimulate the motility but suppress the resorption of isolated rat osteoclasts. J Immunol154: 6065–6072, 1995.
12.
LinS-C, YamateT, TaguchiY, BorbaVZC, GirasoleG, O'brienCA, BellidoT, AbeE, ManolagasSC. Regulation of the gp80 and gp130 subunits of the 11-6 receptor by sex steroids in the murine bone marrow. J Clin Invest100: 1980–1990, 1997.
13.
MiyauraC, KusanoK, MasuzawaT, ChakiO, OnoeY, AoyagiM, SasakiT, TamuraT, KoishiharaY, OhsugiY, SudaT. Endogenous bone-resorbing factors in estrogen deficiency: cooperative effects of IL-1 and IL-6. J bone Miner Res10: 1365–1373, 1995.
14.
DasUN. Interaction(s) between essential fatty acids, eicosanoids, cytokines, growth factors and free radicals: relevance to new therapeutic strategies in rheumatoid arthritis and other collagen vascular diseases. Prostaglandins Leukotrienes Essen Fatty Acids44: 201–210, 1991.
15.
MundyG, GarrettR, HarrisS, ChanJ, ChenD, RossiniG, BoyceB, ZhaoM, GutierrezG. Stimulation of bone formation in vitro and in rodents by statins. Science286: 1946–1949, 1999.
16.
ZhangFL, CaseyPJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem65: 241–269, 1996.
17.
RosensonRS, TangneyCC, CaseyLC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet353: 983–984, 1999.
18.
EdwardsCJ, HartDJ, SpectorTD. Oral statins and increased bone mineral density in postmenopausal women. Lancet355: 2218–2219, 2000.
MeierCR, SchleingerRG, KraenzlinME, SchlegelB, JickH. HMG-CoA reductase inhibitors and the risk of fractures. J Am Med Assoc283: 3205–3210, 2000.
21.
ChanKA, AndradeSE, BolesM, BuistDS, ChaseGA, DonahueJG, GoodmanMJ, GurwitzJH, LaCroixAZ, PiattR. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet355: 2185–2188, 2000.
22.
ReidIR, HagueW, EmbersonJ, BakerJ, TonkinA, HuntD, MacMahonS, SharpeN. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomized controlled trial. Lancet357: 509–512, 2001.
23.
DasUN. Essential fatty acids and osteoporosis. Nutrition16: 386–390, 2000.
24.
WohlGR, LoehrkeL, WatkinsBA, ZernickeRF. Effects of high-fat diet on mature bone mineral content, structure, and mechanical properties. Calcif Tissue Int63: 74–79, 1998.
25.
KrugerMC, HorrobinDF. Calcium metabolism, osteoporosis and essential fatty acids: a review. Prog Lipid Res36: 131–151, 1997.
26.
ProkschE, FeingoldKR, EliasPM. Epidermal HMG-CoA reductase activity in essential fatty acid deficiency: barrier requirements rather than eicosanoid generation regulate cholesterol synthesis. J Invest Dermatol99: 216–220, 1992.
27.
ArnalJF, ClamensS, PechetC, Negre-SalvayreA, AlleraC, GirolamiJ-P, SalvayreR, BayardF. Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. Proc Natl Acad Sci U S A93: 4108–4113, 1996.
28.
HernandezI, DelgadoJL, DiazJ, QuesadaT, TeruelMJ, LlanosMC, CarbonellLF. 17ß-estradiol prevents oxidative stress and decreases blood pressure in ovariectomized rats. Am J Physiol Regul Integr Comp Physiol279: R1599–R1605, 2000.
GuettaV, QuyyumiAA, PrasadA, PanzaJA, WaclawiwM, CannonRIII. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation96: 2795–2801, 1997.
31.
KureishiY, LuoZ, ShiojimaI, BialikA, FultonD, LeferDJ, SessaC, WalshK. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med6: 1004–1010, 2000.
32.
KastenTP, Collin-OsdobyP, PatelN, OsdobyP, KrukowskiM, MiskoTP, SettleSL, CurrieMG, NickolsGA. Potentiation of osteoclast bone resorption activity by inhibition of nitric oxide synthase. Proc Natl Acad Sci U S A91: 3569–3573, 1994.
33.
SimonciniT, GenazzaniAR. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab85: 2966–2969, 2000.
34.
WimalawansaSJ. Restoration of ovariectomy-induced osteopenia by nitroglycerine. Calcif Tissue Int66: 56–60, 2000.
35.
WimalawansaSJ, De MarcoG, GangulaP, YallampalliC. Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone18: 301–304, 1996.
36.
WimalawansaSJ, ChapaMT, YallampalliC, ZhangR, SimmonsDJ. Prevention of corticosteroid-indcued bone loss with nitric oxide donor nitroglycerin in male rats. Bone21: 275–280, 1997.
37.
JamalSA, BrownerWS, BauerDC, CummingsSR. Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res13: 1755–1759, 1998.
38.
WimalawansaSJ. Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study. J Bone Miner Res15: 2240–2244, 2000.
39.
ArmourKE, Van'T HofRJ, GrabowskiPS, ReidDM, RalstonSH. Evidence for a pathogenic role of nitric oxide in inflammation-induced osteoporosis. J Bone Miner Res14: 2137–2142, 1999.
40.
EvansDM, RalstonSH. Nitric oxide and bone. J Bone Miner Res11: 300–305, 1996.
41.
RadomskiMW, PalmerRMJ, MoncadaS. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A87: 10043–10047, 1990.
42.
KanematsuM, IkedaK, YamadaY. Interaction between nitric oxide synthase and cyclooxygenase pathways in osteoblastic MC3T3-E1 cells. J Bone Miner Res12: 1789–1796, 1997.
43.
MohanIK, DasUN. Effect of L-arginine-nitric oxide system on the metabolism of essential fatty acids in chemical-induced diabetes mellitus. Prostaglandins Leukotreine Essen Fatty Acids62: 35–46, 2000.
44.
SureshY, DasUN. Protective action of arachidonic acid against alloxan-induced cytotoxicity and diabetes mellitus. Prostaglandins Leukotreine Essen Fatty Acids64: 37–52, 2001.
45.
MacIntyreI, ZaidiM, Towhidul AlamASM, DattaHK, MoongaBS, LidburyPS, HeckerM, VaneJR. Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci U S A88: 2936–2940, 1991.
